Inhibition of TRPM2 increases sensitivity of neuroblastoma to doxorubicin, and enhances cell death in a number of malignancies including T cell leukemia24, gastric cancer25, and triple-negative and estrogen-receptor positive breast cancer cell lines21,26. The gene discussed is TRPM2; the disease is neuroblastoma.